Prakash Singh Shekhawat
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Prakash Singh Shekhawat has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Prakas Kumar Mandal
Department of Hematology, Nilratan Sircar Medical College and Hospital, Kolkata, India
2 shared publications - Alok Srivastava
Haematology Research Unit, St. John's Research Institute and St. John's Medical College Hospital Bengaluru India
1 shared publication - Arihant Jain
Department of Clinical Hematology and Medical Oncology, PGIMER, Chandigarh, India
1 shared publication - Ashutosh Kumar
Department of Anatomy, All India Institute of Medical Sciences (AIIMS), Patna, India
1 shared publication - Avinash Singh
Paras HMRI Hospital, Patna, India
1 shared publication Avriti Baveja
1 shared publication
Latest Publications
- 19 December 2025
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 42 (5) , 1857-1864
Coagulation Defects in Hemoglobin E β Thalassemia Patients: A Study from a Thalassemia Care Centre (TCU) in Kolkata, India
- 19 December 2025
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 42 (5) , 1857-1864
Coagulation Defects in Hemoglobin E β Thalassemia Patients: A Study from a Thalassemia Care Centre (TCU) in Kolkata, India
- Open Access
- 1 January 2021
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 37 (1) , 1-9
Indian Society of Hematology and Blood Transfusion (ISHBT) Consensus Document on Hematological Practice During COVID-19 Pandemic
The SARS-CoV-2 (COVID-19) pandemic is a worldwide public health emergency with widespread impact on health care delivery. Unforeseen challenges have been noted during administration of usual haematology care in these unusual COVID-19 times. Medical services have been overstretched and frontline health workers have borne the brunt of COVID-19 pandemic. Movement restrictions during lockdown prevented large sections of population from accessing health care, blood banks from holding blood drives, and disrupted delivery of diagnostic hematology services. The disruption in hematology care due to COVID-19 pandemic in India has been disproportionately higher compared to other subspecialities as hematology practice in India remains restricted to major cities. In this review we chronicle the challenges encountered in caring for hematology patients during the COVID-19 pandemic in India and put forth recommendations for minimizing their impact on provision of hematology care with special emphasis on hematology practice in lower and middle income countries (LMICs).
- 1 January 2021
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 37 (1) , 1-9
Open AccessIndian Society of Hematology and Blood Transfusion (ISHBT) Consensus Document on Hematological Practice During COVID-19 Pandemic
The SARS-CoV-2 (COVID-19) pandemic is a worldwide public health emergency with widespread impact on health care delivery. Unforeseen challenges have been noted during administration of usual haematology care in these unusual COVID-19 times. Medical services have been overstretched and frontline health workers have borne the brunt of COVID-19 pandemic. Movement restrictions during lockdown prevented large sections of population from accessing health care, blood banks from holding blood drives, and disrupted delivery of diagnostic hematology services. The disruption in hematology care due to COVID-19 pandemic in India has been disproportionately higher compared to other subspecialities as hematology practice in India remains restricted to major cities. In this review we chronicle the challenges encountered in caring for hematology patients during the COVID-19 pandemic in India and put forth recommendations for minimizing their impact on provision of hematology care with special emphasis on hematology practice in lower and middle income countries (LMICs).
- 28 October 2020
- Published by Taylor & Francis in International Reviews of Immunology
- Vol. 40 (1-2) , 54-71
Pathogenesis guided therapeutic management of COVID-19: an immunological perspective
Lack of standardized therapeutic approaches is arguably the significant contributor to the high burden of mortality observed in the ongoing pandemic of the Coronavirus disease, 2019 (COVID-19). Evidence is accumulating on SARS-CoV-2 specific immune cell dysregulation and consequent tissue injury in COVID-19. Currently, no definite drugs or vaccines are available against the disease; however initial results of the ongoing clinical trials have raised some hope. In this article, taking insights from the emerging empirical evidence about host-virus interactions, we deliberate upon plausible pathogenic mechanisms and suitable therapeutic approaches for COVID-19.
- 28 October 2020
- Published by Taylor & Francis in International Reviews of Immunology
- Vol. 40 (1-2) , 54-71
Pathogenesis guided therapeutic management of COVID-19: an immunological perspective
Lack of standardized therapeutic approaches is arguably the significant contributor to the high burden of mortality observed in the ongoing pandemic of the Coronavirus disease, 2019 (COVID-19). Evidence is accumulating on SARS-CoV-2 specific immune cell dysregulation and consequent tissue injury in COVID-19. Currently, no definite drugs or vaccines are available against the disease; however initial results of the ongoing clinical trials have raised some hope. In this article, taking insights from the emerging empirical evidence about host-virus interactions, we deliberate upon plausible pathogenic mechanisms and suitable therapeutic approaches for COVID-19.